Skip to content
value.today

Thetis Pharmaceuticals LLC

🇺🇸 Southport, Connecticut, USAPharmaceuticalsFounded 2011
Total raised
$14 M
5 rounds on record
Latest round
$1 M
Jun 2022
First round on record
Aug 2011
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Thetis Pharmaceuticals LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2022$1 MNo. 5Under $2 million

Thetis Pharmaceuticals LLC: Raise no. 5, Jun 2022

Investors in this round

9 investors had bought by the notice of Jul 11, 2022: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
$10,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Connecticut

People named in the notice

  • Gary Mathias · Executive Officer, Director · Manager
  • Cynthia F. Green · Director · Manager
  • Dennis F. Willson · Director · Manager
  • Frank C. Sciavolino · Director · Manager
  • Walter Ogier · Director · Manager

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gary Mathias, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 11, 2022. Read the notice at the SEC.

debt, optionsSEC
Jun 2016$4 MNo. 4$2 to $10 million

Thetis Pharmaceuticals LLC: Raise no. 4, Jun 2016

Investors in this round

52 investors had bought by the notice of Jan 17, 2017: 52 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $8 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$200,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Limited Liability Company, incorporated in Connecticut

People named in the notice

  • Frank C Sciavolino · Executive Officer, Director · Manager, President and Chief Scientific Officer
  • Gary F Mathias · Executive Officer, Director · Manager & Chief Executive Officer
  • David M Wurzer · Director · Manager
  • Dennis F Willson · Director · Manager
  • Walter F Ogier · Director · Manager

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Fairport Capital, Inc. (CRD 15034) · broker-dealer Fairport Capital, Inc. (CRD 15034) · Scottsdale, ArizonaSold in all US states

Remarks in the notice

  • On fees: “Broker will be paid a commission of 5% cash and 1.5% equity of total amount sold through broker.”
  • On the use of proceeds: “No payments other than ordinary course employment compensation is being paid to officers or managers.”

Signed by Gary F. Mathias, Manager & CEO. Source: SEC Form D and 1 amendment, newest notice filed Jan 17, 2017. Read the notice at the SEC.

equity, optionsSEC
Jan 2016$1 MNo. 3Under $2 million

Thetis Pharmaceuticals LLC: Raise no. 3, Jan 2016

Investors in this round

16 investors had bought by the notice of Feb 11, 2016: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $4 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Connecticut

People named in the notice

  • Gary F Mathias · Executive Officer, Director · Manager & Chief Executive Officer
  • Alan F Mendelson · Director · Manager
  • David M Wurzer · Director · Manager
  • Dennis M Willson · Director · Manager
  • Frank C Sciavolino · Director · Manager

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “No payments other than ordinary course employment compensation is being paid to officers or managers.”

Signed by Gary F. Mathias, Manager & CRO. Source: SEC Form D, newest notice filed Feb 11, 2016. Read the notice at the SEC.

debt, optionsSEC
Dec 2012$6 MNo. 2$2 to $10 million

Thetis Pharmaceuticals LLC: Raise no. 2, Dec 2012

Investors in this round

32 investors had bought by the notice of Dec 18, 2012: 32 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $7 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Connecticut

People named in the notice

  • Gary F Mathias · Executive Officer, Director · Manager & Chief Financial Officer
  • Michael M Carter · Executive Officer · Secretary
  • Alan F Mendelson · Director · Manager
  • David M Wurzer · Director · Manager
  • Dennis M Willson · Director · Manager
  • Frank C Sciavolino · Director · Manager

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gary F. Mathias, Manager & CFO. Source: SEC Form D, newest notice filed Dec 18, 2012. Read the notice at the SEC.

equitySEC
Aug 2011$2 MNo. 1Under $2 million

Thetis Pharmaceuticals LLC: Raise no. 1, Aug 2011

Investors in this round

14 investors had bought by the notice of Aug 26, 2011: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Limited Liability Company, incorporated in Connecticut

People named in the notice

  • Frank C. Sciavolino · Executive Officer, Director · Manager
  • Gary F. Mathias · Executive Officer · Manager
  • Alan F. Mendelson · Director · Manager
  • David M. Wurzer · Director · Manager

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gary F. Mathias, Manager, CFO, Tres. and Sec.. Source: SEC Form D, newest notice filed Aug 26, 2011. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Thetis Pharmaceuticals LLC chose not to state its revenue in its newest notice of a funding round (Jul 2022).

    SEC Form D · Jul 2022

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jul 2022

That is all the official record says: Thetis Pharmaceuticals LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Thetis Pharmaceuticals LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 52 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Thetis Pharmaceuticals LLC
NameRoleNamed in
Gary MathiasManagerJul 2022
Frank C SciavolinoManager, President and Chief Scientific OfficerJan 2017
Gary F MathiasManager & Chief Executive OfficerJan 2017
Michael M CarterSecretaryDec 2012
Frank C. SciavolinoManagerAug 2011
Gary F. MathiasManagerAug 2011
Cynthia F. GreenManagerJul 2022
Dennis F. WillsonManagerJul 2022
Frank C. SciavolinoManagerJul 2022
Gary MathiasManagerJul 2022
Walter OgierManagerJul 2022
David M WurzerManagerJan 2017
Dennis F WillsonManagerJan 2017
Frank C SciavolinoManager, President and Chief Scientific OfficerJan 2017
Gary F MathiasManager & Chief Executive OfficerJan 2017
Walter F OgierManagerJan 2017
Alan F MendelsonManagerJun 2016
Dennis M WillsonManagerJun 2016
Alan F. MendelsonManagerAug 2011
David M. WurzerManagerAug 2011